Crizotinib, a selective tyrosine kinase inhibitor (TKI), shows marked activity in patients whose lung cancers harbor fusions in the gene encoding anaplastic lymphoma receptor tyrosine kinase (ALK), but its efficacy is limited by variable primary responses and acquired resistance. In work arising from the clinical observation of a patient with ALK fusion–positive lung cancer who had an exceptional response to an insulin-like growth factor 1 receptor (IGF-1R)-specific antibody, we define a therapeutic synergism between ALK and IGF-1R inhibitors. Similar to IGF-1R, ALK fusion proteins bind to the adaptor insulin receptor substrate 1 (IRS-1), and IRS-1 knockdown enhances the antitumor effects of ALK inhibitors. In models of ALK TKI resistance, the IGF-1R pathway is activated, and combined ALK and IGF-1R inhibition improves therapeutic efficacy. Consistent with this finding, the levels of IGF-1R and IRS-1 are increased in biopsy samples from patients progressing on crizotinib monotherapy. Collectively these data support a role for the IGF-1R–IRS-1 pathway in both ALK TKI–sensitive and ALK TKI–resistant states and provide a biological rationale for further clinical development of dual ALK and IGF-1R inhibitors.
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Grande, E., Bolos, M.V. & Arriola, E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol. Cancer Ther. 10, 569–579 (2011).
Camidge, D.R. et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 13, 1011–1019 (2012).
Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4, 120ra117 (2012).
Doebele, R.C. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18, 1472–1482 (2012).
Lovly, C.M. & Pao, W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci. Transl. Med. 4, 120ps122 (2012).
Tanizaki, J. et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK–positive non-small cell lung cancer. Clin. Cancer Res. 18, 6219–6226 (2012).
Iyer, G. et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221 (2012).
Shaw, A.T. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247–4253 (2009).
Boik, J.C., Newman, R.A. & Boik, R.J. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study. Stat. Med. 27, 1040–1061 (2008).
Mulvihill, M.J. et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med. Chem. 1, 1153–1171 (2009).
Metz, H.E. & Houghton, A.M. Insulin receptor substrate regulation of phosphoinositide 3-kinase. Clin. Cancer Res. 17, 206–211 (2011).
Yang, X. et al. Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Cancer Res. 71, 5965–5975 (2011).
Chen, Z. et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 70, 9827–9836 (2010).
Lovly, C.M. et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res. 71, 4920–4931 (2011).
Katayama, R. et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl. Acad. Sci. USA 108, 7535–7540 (2011).
Guix, M. et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118, 2609–2619 (2008).
Cortot, A.B. et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res. 73, 834–843 (2013).
García-Echeverria, C. et al. In vivo antitumor activity of NVP-AEW541—a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5, 231–239 (2004).
Morgillo, F. et al. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin. Cancer Res. 13, 2795–2803 (2007).
Vazquez-Martin, A. et al. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Sci. Rep. 3, 2560 (2013).
Chmielecki, J. et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med. 3, 90ra59 (2011).
Ohashi, K. et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl. Acad. Sci. USA 109, E2127–E2133 (2012).
Suehara, Y. et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin. Cancer Res. 18, 6599–6608 (2012).
Shaw, A.T. et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 1189–1197 (2014).
Galkin, A.V. et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc. Natl. Acad. Sci. USA 104, 270–275 (2007).
Morris, S.W. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281–1284 (1994).
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
Gainor, J.F. et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin. Cancer Res. 19, 4273–4281 (2013).
Dunning, M.J., Smith, M.L., Ritchie, M.E. & Tavare, S. Beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23, 2183–2184 (2007).
Su, Z. et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J. Mol. Diagn. 13, 74–84 (2011).
This work was supported by the Vanderbilt-Ingram Cancer Center Core grant (P30-CA68485), a career development award from the Vanderbilt Specialized Program of Research Excellence in Lung Cancer grant (CA90949), US National Cancer Institute grants R01CA121210 and P01CA129243 and the Joyce Family Foundation. C.M.L. was additionally supported by a US National Institutes of Health (NIH) K12 training grant (K12 CA9060625), an American Society of Clinical Oncology Young Investigator Award, a Uniting Against Lung Cancer grant and a Damon Runyon Clinical Investigator Award. C.M.L. was the Carol and Jim O'Hare chief fellow from 7/1/2011 through 6/30/2012. L.C.H. and R.B. were supported by the Deutsche Forschungsgemeinschaft (SFB 832, Tumormicromilieu) and the German Cancer Aid (Center for Integrated Oncology (CIO) Köln-Bonn). M. Bos was supported by the European Regional Development Fund grant number FKZ:005-111-0027. G.M.W. was supported by the Victorian Cancer Agency grant TS10_01. K.-K.W. is supported by the NIH CA122794, CA140594, CA163896, CA166480 and CA154303 grants. P.K.P. was supported by a Uniting Against Lung Cancer grant. R.K.T. is supported by the EU-Framework Programme CURELUNG (HEALTH-F2-2010-258677), the Deutsche Forschungsgemeinschaft through TH1386/3-1 and SFB832 (TP6), the German Ministry of Science and Education (BMBF) as part of the NGFNplus program (grant 01GS08100) and the Deutsche Krebshilfe as part of the Oncology Centers of Excellence funding program. S.P. was supported by a grant from the Rudolph Becker Foundation. J.W. was supported by the German Cancer Aid (CIO Köln-Bonn), the Federal Ministry of Education and Research (NGFNplus) and the Ministry of Economy, Energy, Industry and Craft of North Rhine-Westfalia (NRW) in the PerMed NRW framework program. Z.Z. was supported by NIH R01LM011177. We thank J. Sosman and C. Arteaga for their critical review of this manuscript, C. Liang (Xcovery) for providing X-376 and A. Nashabi for administrative assistance. Australian specimens were processed by the Victorian Cancer Biobank. The human anaplastic lymphoma cell line, SUDHL-1, was a generous gift from S. Morris of St. Jude Children's Research Hospital.
The authors declare no competing financial interests.
About this article
Cite this article
Lovly, C., McDonald, N., Chen, H. et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer. Nat Med 20, 1027–1034 (2014). https://doi.org/10.1038/nm.3667
Recurrent hyperglycemic hyperosmolar state after re-administration of dose-reduced ceritinib, an anaplastic lymphoma kinase inhibitor
Diabetology International (2020)
Expert Review of Anticancer Therapy (2020)
Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma
Investigational New Drugs (2020)
Seminars in Cancer Biology (2020)